Synergistic effects of biomaterials and extracellular vesicles in treating myocardial infarction: A systematic review of preclinical studies
Source abstract
Abstract
Extracellular vesicles (EVs) combined with biomaterials have shown promise in treating myocardial infarction (MI), with potential to alleviate inflammation, oxidative stress, and apoptosis while improving cardiac function. However, systematic evaluation is needed. This meta-analysis utilized data from PubMed, Web of Science, Scopus, EMBASE, and Ovid medicine from their inception to May 2025. Relevant outcomes were analyzed using GetData Graph Digitizer 2.26 and Review Manager 5.4 software. The quality of studies was assessed using the SYRCLE risk of bias tool and CAMARADES checklist. We measured 12 indicators across cardiac function, fibrosis, apoptosis, and inflammation. The meta-analysis included 33 studies. Compared to EV monotherapy, the combination of EVs with biomaterials significantly improved several cardiac functions and structural parameters. These include: Ejection Fraction (SMD = 1.79; p < 0.00001); Fractional Shortening (SMD = 1.61; p < 0.00001); Myocardial Fibrosis (SMD = -1.83; p = 0.002); Additionally, IL-6 (SMD = -2.55; p = 0.01) and TNF-α (SMD = -1.18; p = 0.01), as well as apoptosis levels (SMD = -3.72; p < 0.0001), were markedly reduced. Among them, intramyocardial injection of MSC-derived EVs combined with hydrogel is the most widely used combination therapy. EVs combined with biomaterials enhance cardiac recovery in MI models with no significant safety issues, highlighting their potential therapeutic benefits. STATEMENT OF SIGNIFICANCE: Myocardial infarction (MI) is one of the leading causes of death and disease burden. Over the past 20 years, extracellular vesicles (EVs) have undergone a remarkable journey and are now poised on the brink of becoming the next generation of cell-free therapeutic tools. Our study aims to quantitatively analyze the efficacy and safety of combining biomaterials with EVs compared to EVs alone in MI through a meta-analytical mapping approach. This is the comprehensive meta-analysis summarizing the effectiveness and safety of various biomaterials combined with EV therapy, highlighting the role of biomaterials in advancing the field. It provides valuable insights for researchers exploring the clinical translation of EV-based therapies.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Extracellular vesicles in disease · Tissue Engineering and Regenerative Medicine · Cardiovascular Disease and Adiposity
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (71)
Show source-provided references
1. Incidence, risk factors and outcome of young patients with myocardial infarction10.1136/heartjnl-2019-316067 ↗
2. Kedhi · Lancet · 2025 · 404 · 259310.1016/S0140-6736(24)02100-7 ↗
3. Post-myocardial infarction heart failure10.1016/j.jchf.2017.09.015 ↗
4. Injury minimization after myocardial infarction: focus on extracellular vesicles10.1093/eurheartj/ehae089 ↗
5. Advances in the study of exosomes derived from mesenchymal stem cells and cardiac cells for the treatment of myocardial infarction10.1186/s12964-023-01227-9 ↗
6. The role of cardiac pericytes in health and disease: therapeutic targets for myocardial infarction10.1038/s41569-023-00913-y ↗
7. Apoptosis and myocardial infarction: role of ncRNAs and exosomal ncRNAs10.2217/epi-2022-0451 ↗
8. M2 macrophage-derived exosomes carry miR-1271-5p to alleviate cardiac injury in acute myocardial infarction through down-regulating SOX610.1016/j.molimm.2021.05.006 ↗
9. The orchestration of cell-cycle reentry and ribosome biogenesis network is critical for cardiac repair10.7150/thno.96460 ↗
10. Interleukin-10 deficiency alters endothelial progenitor cell-derived exosome reparative effect on myocardial repair via integrin-linked kinase enrichment10.1161/CIRCRESAHA.119.315829 ↗
11. Microneedle patch loaded with exosomes containing MicroRNA-29b prevents cardiac fibrosis after myocardial infarction
12. Inhalable Stem Cell Exosomes Promote Heart Repair After Myocardial Infarction10.1161/CIRCULATIONAHA.123.065005 ↗
13. Locally delivered hydrogels with controlled release of nanoscale exosomes promote cardiac repair after myocardial infarction10.1016/j.jconrel.2024.02.035 ↗
14. Pooling of animal experimental data reveals influence of study design and publication bias10.1161/01.STR.0000125719.25853.20 ↗
15. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews10.1016/j.ijsu.2021.105906 ↗
16. Stem cell therapy for Crohn's disease: systematic review and meta-analysis of preclinical and clinical studies10.1186/s13287-021-02533-0 ↗
17. Sustained release of endothelial progenitor cell-derived extracellular vesicles from shear-thinning hydrogels improves angiogenesis and promotes function after myocardial infarction10.1093/cvr/cvy067 ↗
18. Delayed delivery of endothelial progenitor cell-derived extracellular vesicles via shear thinning gel improves postinfarct hemodynamics10.1016/j.jtcvs.2019.06.017 ↗
19. Ameliorating impaired cardiac function in myocardial infarction using exosome-loaded gallic-acid-containing polyurethane scaffolds
20. Mesenchymal stem cell-derived extracellular vesicles alone or in conjunction with a SDKP-conjugated self-assembling peptide improve a rat model of myocardial infarction10.1016/j.bbrc.2020.02.009 ↗
21. Engineered bone marrow mesenchymal stem cell-derived exosomes loaded with miR302 through the cardiomyocyte specific peptide can reduce myocardial ischemia and reperfusion (I/R) injury10.1186/s12967-024-04981-7 ↗
22. Human umbilical cord mesenchymal stem cell derived exosomes encapsulated in functional peptide hydrogels promote cardiac repair10.1039/C9BM00101H ↗
23. Islet-1 mesenchymal stem cells-derived exosome-incorporated angiogenin-1 hydrogel for enhanced acute myocardial infarction therapy10.1021/acsami.2c04686 ↗
24. Silk fibroin and hydroxypropyl cellulose composite injectable hydrogel-containing extracellular vesicles for myocardial infarction repair10.1088/2057-1976/ad40b2 ↗
25. Hyaluronic acid stimulation of stem cells for cardiac repair: a cell-free strategy for myocardial infarct10.1186/s12951-024-02410-x ↗
26. Cardiac repair using regenerating neonatal heart tissue-derived extracellular vesicles10.1038/s41467-025-56384-x ↗
27. Cardiac recovery via extended cell-free delivery of extracellular vesicles secreted by cardiomyocytes derived from induced pluripotent stem cells10.1038/s41551-018-0229-7 ↗
28. Incorporation of small extracellular vesicles in sodium alginate hydrogel as a novel therapeutic strategy for myocardial infarction10.7150/thno.32637 ↗
29. Enhancing neovascularization post-myocardial infarction through injectable hydrogel functionalized with endothelial-derived EVs10.1088/1758-5090/ad6190 ↗
30. Acellular cardiac scaffolds enriched with MSC-derived extracellular vesicles limit ventricular remodelling and exert local and systemic immunomodulation in a myocardial infarction porcine model10.7150/thno.72289 ↗
31. Release of exosomes from injectable silk fibroin and alginate composite hydrogel for treatment of myocardial infarction10.1177/08853282241251610 ↗
32. Biomaterial-embedded extracellular vesicles improve recovery of the dysfunctional myocardium10.1016/j.biomaterials.2022.121877 ↗
33. Fabrication of blended nanofibrous cardiac patch transplanted with TGF-β3 and human umbilical cord MSCs-derived exosomes for potential cardiac regeneration after acute myocardial infarction10.1016/j.nano.2023.102708 ↗
34. An injectable exosome-loaded hyaluronic acid-polylysine hydrogel for cardiac repair via modulating oxidative stress and the inflammatory microenvironment
35. Oxygen releasing and antioxidant breathing cardiac patch delivering exosomes promotes heart repair after myocardial infarction
36. Injection-free delivery of MSC-derived extracellular vesicles for myocardial infarction therapeutics10.1002/adhm.202100312 ↗
37. Targeting regenerative exosomes to myocardial infarction using cardiac homing peptide10.7150/thno.20524 ↗
38. HIF-1α overexpression in mesenchymal stem cell-derived exosome-encapsulated arginine-glycine-aspartate (RGD) hydrogels boost therapeutic efficacy of cardiac repair after myocardial infarction
39. Intranasal delivery of endothelial cell-derived extracellular vesicles with supramolecular gel attenuates myocardial ischemia-reperfusion injury10.2147/IJN.S420301 ↗
40. Improving therapeutic effects of exosomes encapsulated gelatin methacryloyl/hyaluronic acid blended and oxygen releasing injectable hydrogel by cardiomyocytes induction and vascularization in rat myocardial infarction model
41. Cardiac organoid model inspired micro-robot smart patch to treat myocardial infarction
42. A novel conductive polypyrrole-chitosan hydrogel containing Human endometrial mesenchymal stem cell-derived exosomes facilitated sustained release for cardiac repair
43. A minimally invasive exosome spray repairs heart after myocardial infarction10.1021/acsnano.1c00628 ↗
44. Extracellular vesicles engineering by silicates-activated endothelial progenitor cells for myocardial infarction treatment in male mice10.1038/s41467-023-37832-y ↗
45. Hydrogel-load exosomes derived from dendritic cells improve cardiac function via Treg cells and the polarization of macrophages following myocardial infarction10.1186/s12951-021-01016-x ↗
46. Engineered nanovesicles mediated cardiomyocyte survival and neovascularization for the therapy of myocardial infarction10.1016/j.colsurfb.2024.114135 ↗
47. Minimally invasive delivery of therapeutic agents by hydrogel injection into the pericardial cavity for cardiac repair10.1038/s41467-021-21682-7 ↗
48. Restoring cardiac functions after myocardial infarction-ischemia/reperfusion via an exosome anchoring conductive hydrogel10.1021/acsami.1c16481 ↗
49. Combinatorial effect of biomaterials and extracellular vesicle therapy for heart failure with reduced ejection fraction: a systematic review of preclinical studies10.1002/adhm.202301980 ↗
50. Mesenchymal stromal cells for improvement of cardiac function following acute myocardial infarction: a matter of timing10.1152/physrev.00009.2023 ↗
51. Cell-based and selected Cell-free therapies for myocardial infarction: how do they compare to the current treatment options?10.3390/ijms231810314 ↗
52. Endocytosis of extracellular vesicles and release of their cargo from endosomes10.1021/acsnano.9b10033 ↗
53. Extracellular vesicles as a next-generation drug delivery platform10.1038/s41565-021-00931-2 ↗
54. Glucose starvation in cardiomyocytes enhances exosome secretion and promotes angiogenesis in endothelial cells10.1371/journal.pone.0138849 ↗
55. Low pH increases the yield of exosome isolation10.1016/j.bbrc.2015.03.172 ↗
56. Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications10.2147/IJN.S264498 ↗
57. Engineered exosomes with ischemic myocardium-targeting peptide for targeted therapy in myocardial infarction10.1161/JAHA.118.008737 ↗
58. Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: strategies and significance10.1016/j.jconrel.2020.07.042 ↗
59. Vectorization of biomacromolecules into cells using extracellular vesicles with enhanced internalization induced by macropinocytosis10.1038/srep34937 ↗
60. Hypoxia and TNF-alpha modulate extracellular vesicle release from human induced pluripotent stem cell-derived cardiomyocytes10.1002/jev2.70000 ↗
61. Atorvastatin-pretreated mesenchymal stem cell-derived extracellular vesicles promote cardiac repair after myocardial infarction via shifting macrophage polarization by targeting microRNA-139-3p/Stat1 pathway10.1186/s12916-023-02778-x ↗
62. Anti-inflammatory, Anti-fibrotic and pro-cardiomyogenic effects of genetically engineered extracellular vesicles enriched in miR-1 and miR-199a on Human cardiac fibroblasts10.1007/s12015-023-10621-2 ↗
63. Manufacturing and characterization of extracellular vesicles from umbilical cord-derived mesenchymal stromal cells for clinical testing10.1016/j.jcyt.2018.12.006 ↗
64. The discovery of extracellular vesicles and their emergence as a next-generation therapy10.1161/CIRCRESAHA.123.323054 ↗
65. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction10.1126/scitranslmed.3005503 ↗
66. Stem cell and exosome therapies for regenerating damaged myocardium in heart failure10.1016/j.lfs.2024.122858 ↗
67. Exosome-mediated benefits of cell therapy in mouse and Human models of duchenne muscular dystrophy10.1016/j.stemcr.2018.01.023 ↗
68. MiRNA profiles of extracellular vesicles secreted by mesenchymal stromal cells-can they predict potential off-target effects?10.3390/biom10091353 ↗
69. GMP-compliant extracellular vesicles derived from umbilical cord mesenchymal stromal cells: manufacturing and pre-clinical evaluation in ARDS treatment10.1016/j.jcyt.2024.04.074 ↗
70. Dosing extracellular vesicles10.1016/j.addr.2021.113961 ↗
71. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches10.1002/jev2.12404 ↗